When Are Oncotype DX and MammaPrint Used in Breast Cancer?

Genomic tests like Oncotype DX and MammaPrint are used to help decide if adding chemotherapy to your treatment plan will be beneficial for early-stage, hormone-receptor-positive (HR-positive), HER2-negative breast cancer ^[1].

These tests are performed on a sample of your tumor tissue (from a biopsy or surgery) ^[2][3]. They are not the same as genetic blood tests (like BRCA testing) that look for inherited cancer risks. Instead, they analyze the activity of specific genes within the tumor itself to estimate the risk of the cancer returning (distant recurrence) and whether chemotherapy is likely to lower that risk ^[1][4].

It is important to know that these tests do not guarantee that you will or won’t have a recurrence. Instead, they provide a group-level estimate of benefit to help you and your doctor make an informed decision ^[1].

The Role of Menopause

Because breast cancer behaves differently depending on the estrogen in your body, how your doctor interprets test results depends heavily on your menopausal status and whether cancer has spread to your lymph nodes ^[5][1].

In major clinical trials (like TAILORx and RxPONDER), researchers often used age 50 as a proxy for menopause ^[6][5]. However, age is not the same as menopausal status. Some women under 50 are postmenopausal, and some over 50 are premenopausal. Your clinical team will determine your true menopausal (ovarian function) status, which is what truly matters for your treatment decisions ^[1].

Node-Negative Breast Cancer

If your cancer has not spread to any lymph nodes, genomic testing is commonly used to see if chemotherapy can be safely omitted while still receiving endocrine (anti-estrogen) therapy ^[1].

• For postmenopausal women: With the 21-gene Oncotype DX test, a recurrence score below 26 generally indicates that chemotherapy will not provide significant benefit, and endocrine therapy without chemotherapy is usually recommended ^[4]. For the 70-gene MammaPrint test, a “low genomic risk” result can also support omitting chemotherapy, particularly if the tumor has “clinically high-risk” features (such as being larger or faster-growing) ^[7].
• For premenopausal women: The evidence is different. With Oncotype DX, a score below 16 suggests chemotherapy offers little to no benefit ^[8]. However, the TAILORx trial found that premenopausal women with scores between 16 and 25 may still get some benefit from chemotherapy, depending on their exact score and clinical risk ^[8][6]. Therefore, a score in this middle range requires a careful discussion.

1 to 3 Positive Lymph Nodes

If cancer is found in 1 to 3 lymph nodes, the decision relies even more heavily on menopausal status ^[1].

• For postmenopausal women: If the Oncotype DX score is between 0 and 25, or the MammaPrint result is low risk, major trials have shown no significant benefit to adding chemotherapy ^[5][9]. These patients can typically be treated with endocrine therapy without chemotherapy ^[1].
• For premenopausal women: The RxPONDER trial showed that premenopausal women with 1 to 3 positive nodes do benefit from chemotherapy, even if their genomic test score is low (0-25) ^[5]. Because of this, guidelines state that a low Oncotype DX or MammaPrint score should not be used as a reason to automatically skip chemotherapy in premenopausal women with positive nodes ^[1][10].

(Researchers suspect that part of the reason chemotherapy helps younger women is that it causes the ovaries to temporarily or permanently stop producing estrogen, which starves the cancer. While studies are investigating whether medically shutting down the ovaries (ovarian suppression) combined with endocrine therapy can replace chemotherapy for these patients, this has not yet been fully established ^[10][11].)

What Do High Scores Mean?

If you receive a high Oncotype DX score (generally 26 or higher) or a “high genomic risk” MammaPrint result, it indicates that the cancer has a higher risk of recurrence and that chemotherapy is more likely to provide a meaningful benefit in reducing that risk ^[4]. A high score generally strengthens the recommendation for chemotherapy, though it is not an automatic mandate; the decision remains yours to make with your care team.

When Are These Tests Not Used?

Genomic tests are not appropriate for everyone. They are generally not recommended to guide the decision to omit standard treatments if:

• You have 4 or more positive lymph nodes: The risk of recurrence is higher, and chemotherapy is often recommended, though treatment remains individualized based on your health and preferences ^[1][7].
• Your breast cancer is HER2-positive or Triple-Negative: These subtypes require specific targeted therapies or chemotherapy based on established guidelines; Oncotype DX and MammaPrint are not recommended for deciding whether to omit standard treatments in these subtypes ^[1][7].
• The tumor is extremely small and low clinical risk: If a tumor is very small, low-grade, and lacking high-risk features, chemotherapy often wouldn’t be considered, making testing unnecessary ^[12][13]. However, there is no universal size rule.

Putting the Whole Picture Together

Your doctor will not look at a genomic test score in isolation. The result is always combined with clinical and pathology features ^[14], including:

• Tumor size and grade: The physical size of the tumor and its grade (how abnormal and biologically aggressive the cells appear) ^[15].
• Nodal status: The exact number of lymph nodes involved ^[15].
• Your overall health: Your ability to tolerate side effects and your personal priorities ^[1][16].

To help combine these factors, doctors sometimes use tools like RSClin. This is a calculator validated for specific early-stage HR-positive/HER2-negative, node-negative patients that combines the Oncotype score with age, tumor size, and tumor grade to give a highly personalized estimate of your absolute chemotherapy benefit ^[17].

If your genomic score and your tumor’s features seem to tell two different stories, your care team will discuss what this means for you. There is no one-size-fits-all answer, and the goal is always a shared decision that balances reducing your risk with maintaining your quality of life ^[10][1].